JP2021185201A - コラーゲン7組成物及びそれを用いる方法 - Google Patents
コラーゲン7組成物及びそれを用いる方法 Download PDFInfo
- Publication number
- JP2021185201A JP2021185201A JP2021146575A JP2021146575A JP2021185201A JP 2021185201 A JP2021185201 A JP 2021185201A JP 2021146575 A JP2021146575 A JP 2021146575A JP 2021146575 A JP2021146575 A JP 2021146575A JP 2021185201 A JP2021185201 A JP 2021185201A
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- collagen
- composition
- arginine
- certain embodiments
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 74
- 102000008186 Collagen Human genes 0.000 title claims abstract description 34
- 108010035532 Collagen Proteins 0.000 title claims abstract description 34
- 229920001436 collagen Polymers 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title abstract description 10
- 239000004475 Arginine Substances 0.000 claims abstract description 23
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 23
- 229930006000 Sucrose Natural products 0.000 claims abstract description 22
- 239000005720 sucrose Substances 0.000 claims abstract description 22
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims abstract description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 40
- 239000011780 sodium chloride Substances 0.000 claims description 21
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 20
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 20
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 20
- 229940068977 polysorbate 20 Drugs 0.000 claims description 20
- 239000001488 sodium phosphate Substances 0.000 claims description 19
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 19
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 19
- 239000001509 sodium citrate Substances 0.000 claims description 16
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 239000011521 glass Substances 0.000 claims description 3
- 229920000515 polycarbonate Polymers 0.000 claims description 3
- 239000004417 polycarbonate Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- 235000009697 arginine Nutrition 0.000 description 20
- 235000002639 sodium chloride Nutrition 0.000 description 20
- 238000009472 formulation Methods 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 238000002360 preparation method Methods 0.000 description 16
- 239000000872 buffer Substances 0.000 description 13
- 238000003860 storage Methods 0.000 description 13
- 239000000126 substance Substances 0.000 description 13
- 208000010975 Dystrophic epidermolysis bullosa Diseases 0.000 description 12
- 208000004298 epidermolysis bullosa dystrophica Diseases 0.000 description 12
- 239000004094 surface-active agent Substances 0.000 description 11
- 238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 8
- 229930064664 L-arginine Natural products 0.000 description 8
- 235000014852 L-arginine Nutrition 0.000 description 8
- 239000000835 fiber Substances 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- 210000004207 dermis Anatomy 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 239000002738 chelating agent Substances 0.000 description 5
- 229920000136 polysorbate Polymers 0.000 description 5
- 229950008882 polysorbate Drugs 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical group [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 4
- 102000016359 Fibronectins Human genes 0.000 description 4
- 108010067306 Fibronectins Proteins 0.000 description 4
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
- 210000002469 basement membrane Anatomy 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002615 epidermis Anatomy 0.000 description 4
- 239000003797 essential amino acid Substances 0.000 description 4
- 235000020776 essential amino acid Nutrition 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000010257 thawing Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000007798 antifreeze agent Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 3
- 229940068968 polysorbate 80 Drugs 0.000 description 3
- 229920000053 polysorbate 80 Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000159 protein binding assay Methods 0.000 description 3
- 230000037390 scarring Effects 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 101100496574 Mus musculus Col7a1 gene Proteins 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000005538 encapsulation Methods 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 210000004744 fore-foot Anatomy 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 239000013628 high molecular weight specie Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000013627 low molecular weight specie Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000015380 nutritional deficiency disease Diseases 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 235000011083 sodium citrates Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 235000011008 sodium phosphates Nutrition 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 108700037244 Complement Component 7 Deficiency Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 102000014961 Protein Precursors Human genes 0.000 description 1
- 108010078762 Protein Precursors Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229960000276 acetophenazine Drugs 0.000 description 1
- NUKVZKPNSKJGBK-SPIKMXEPSA-N acetophenazine dimaleate Chemical compound [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.C12=CC(C(=O)C)=CC=C2SC2=CC=CC=C2N1CCCN1CCN(CCO)CC1 NUKVZKPNSKJGBK-SPIKMXEPSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000012870 ammonium sulfate precipitation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000008935 histological improvement Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- -1 homotrimer Substances 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003739 neck Anatomy 0.000 description 1
- 150000002840 non-reducing disaccharides Chemical class 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 230000008646 thermal stress Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000012905 visible particle Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/014—Hydrolysed proteins; Derivatives thereof from animals from connective tissue peptides, e.g. gelatin, collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/20—Halogens; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/24—Phosphorous; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4993—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Birds (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Cosmetics (AREA)
Abstract
Description
特定の実施形態では、リン酸ナトリウムは、100mM〜1mM、50mM〜5mM、25mM〜5mM、10mM〜5mM、10mM〜1mMの範囲又は約10mMの量で存在する。
特定の実施形態では、アルギニンは、200mM〜5mM、150mM〜50mM、100mM〜75mMの範囲、又は約100mMの量で存在する。
コラーゲン7組成物は、増加した安定性を有する。特定の実施形態では、組成物は、1リットルのポリカーボネートボトル内(組成物500mL)、−65±5℃又は−20±5℃で貯蔵後、3か月間安定である。特定の実施形態では、組成物は、10cm3(10cc)のガラスバイアル内(組成物5.5mL)、−65±5℃又は−20±5℃で貯蔵後、6か月間安定である。特定の実施形態では、組成物は、25±3℃で2週間の貯蔵後、安定である。特定の実施形態では、組成物は、5±3℃で最大1か月間の貯蔵後、安定である。
別の態様は、DEBを治療する方法であって、本明細書に記載されるような組換えコラーゲン7組成物を有効量でそれを必要とする対象に投与するステップを含む、方法を対象とする。
Biol Chem)、2002年、第277巻、第18号、p.2118〜2124)。
凍結/解凍特性及び熱安定性を比較するため、以前に用いたPBS製剤を含む5つの製剤を選択した。これらの製剤を表1に列挙する。
rC7を血流中に静脈内注射するときに何が生じるかを知ることは困難である。しかし、10%ウシ血清を含有し、37℃で保持される緩衝液などのより生理学的関連条件にタンパク質が曝露するときの任意の変化について監視することにより、生成物の品質変化についての可能性を評価することは可能である。rC7タンパク質は、可溶性凝集及び沈殿の傾向がある。これらの事象は、一般的な分析技術を通じて監視することができる。タンパク質含量における変化について監視するため、A280の吸光度を用いる。不可溶性微粒子の形成に起因する混濁度における変化について監視するため、A320の吸光度を用いる。HMW及び/又はLMW種が形成する場合の可溶性タンパク質における変化について監視するため、SEC−HPLCを用いる。血清効果の影響を最大化するため、緩衝液を等量の血清で希釈し、0.5mg/mLの最終タンパク質濃度、(第I相製剤中)rC7の存在下でインキュベートした。体温をシミュレートするため、全試料を37℃で1時間保持した。これらの結果のまとめを表5に列挙する。その結果によると、生理学的培地への37℃で1時間の曝露後、タンパク質含量(A280)、又は混濁度(A320)に変化がないことが示された。したがって、データは、血清へのrC7送達の希釈時に即時性の溶解度制限が明白でないことを示唆している。
SEC−HPLC特性によると、様々な試験緩衝液マトリックスに37℃で1時間曝露後、不可溶性凝集体の増加が認められないことが確認された。図5。様々な緩衝液への曝露により、おそらくはαヘリックスの可動性の増加に起因して、ピークの低分子量側領域における初期変化が惹起される。
実施例2
初期開発研究に基づき、10mMのリン酸ナトリウム、5mMのクエン酸ナトリウム、70mMの塩化ナトリウム、100mMのアルギニン、50mMのスクロース、0.05%のポリソルベート20、及び約7.1のpHを含む製剤を、DEBのマウスモデルにおけるCol7a1−/−マウスへの投与に用いた。
舌における表皮と真皮との間の完全な閉鎖(すなわち分離なし)を伴うマウスの割合は、被験物質1、被験物質2、及び溶媒対照を投与したCol7a1−/−マウスにおいて各々、50%(26中12)、63%(26中15)、及び10%(10中1)であった。真皮−上皮分離の完全な閉鎖を伴うCol7a1−/−マウスの割合は、rC7治療マウスにおいて、溶媒対照よりも高かった(被験物質1対溶媒、フィッシャーp=0.06、被験物質2対溶媒、フィッシャーp=0.02)。真皮−上皮分離の閉鎖を伴うCol7a1−/−マウスの割合は、rC7治療マウス間で異ならなかった(フィッシャーp=0.58)。
この試験では、DEBの新生児マウスモデルでの試験対象のrC7組成物における有効性が実証された。詳細には、舌及び皮膚における真皮−上皮BMZに対して分布した両被験物質が、真皮−上皮分離を修正し、その結果、Col7a1−/−マウスにおける単回静脈内注射後、生存において、溶媒対照と比べて統計学的に有意な改善をもたらした。
Claims (9)
- 組換えコラーゲン7、約10mMのリン酸ナトリウム、約5mMのクエン酸ナトリウム、約70mMの塩化ナトリウム、約100mMのアルギニン、約1.7%(w/v)のスクロース、及び約0.05%のポリソルベート20を含んでなる、組成物。
- 7.0〜7.2のpHを有する、請求項1に記載の組成物。
- 前記組換えコラーゲン7がヒトコラーゲン7である、請求項1又は2に記載の組成物。
- 組換えコラーゲン7、約10mMのリン酸ナトリウム、約5mMのクエン酸ナトリウム、約70mMの塩化ナトリウム、約100mMのアルギニン、約50mMのスクロース、約0.05%のポリソルベート20及び1つ以上の薬学的に許容できる賦形剤を含んでなる、医薬組成物。
- 7.0〜7.2のpHを有する、請求項4に記載の医薬組成物。
- 前記組換えコラーゲン7がヒトコラーゲンである、請求項4又は5に記載の医薬組成物。
- (a)請求項1〜3のいずれか一項に記載の前記組成物又は請求項4〜6のいずれか一項に記載の前記医薬組成物500mLが1リットルのポリカーボネートボトル内で貯蔵されるとき、−65±5℃又は−20±5℃で3か月間;
(b)請求項1〜3のいずれか一項に記載の前記組成物又は請求項4〜6のいずれか一項に記載の前記医薬組成物5.5mLが10cm3(10cc)のガラスバイアル内で貯蔵されるとき、−65±5℃又は−20±5℃で6か月間;
(c)25±3℃で2週間;及び
(d)5±3℃で最大1か月間、
のうちの少なくとも1つの条件で安定である、請求項1〜3のいずれか一項に記載の組成物又は請求項4〜6のいずれか一項に記載の医薬組成物。 - 栄養障害型表皮水疱症の治療に用いられる、請求項1〜3のいずれか一項に記載の組成物又は請求項4〜7のいずれか一項に記載の医薬組成物。
- 請求項1〜3のいずれか一項に記載の前記組成物又は請求項4〜8のいずれか一項に記載の前記医薬組成物であって、栄養障害型表皮水疱症を治療するために使用する、請求項1〜3のいずれか一項に記載の前記組成物又は請求項4〜8のいずれか一項に記載の前記医薬組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2023171324A JP2023166014A (ja) | 2015-12-23 | 2023-10-02 | コラーゲン7組成物及びそれを用いる方法 |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562387241P | 2015-12-23 | 2015-12-23 | |
US62/387,241 | 2015-12-23 | ||
US201662278816P | 2016-01-14 | 2016-01-14 | |
US62/278,816 | 2016-01-14 | ||
US201662293209P | 2016-02-09 | 2016-02-09 | |
US62/293,209 | 2016-02-09 | ||
JP2018533834A JP6943858B2 (ja) | 2015-12-23 | 2016-12-21 | コラーゲン7組成物及びそれを用いる方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018533834A Division JP6943858B2 (ja) | 2015-12-23 | 2016-12-21 | コラーゲン7組成物及びそれを用いる方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023171324A Division JP2023166014A (ja) | 2015-12-23 | 2023-10-02 | コラーゲン7組成物及びそれを用いる方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2021185201A true JP2021185201A (ja) | 2021-12-09 |
Family
ID=59091196
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018533834A Active JP6943858B2 (ja) | 2015-12-23 | 2016-12-21 | コラーゲン7組成物及びそれを用いる方法 |
JP2021146575A Pending JP2021185201A (ja) | 2015-12-23 | 2021-09-09 | コラーゲン7組成物及びそれを用いる方法 |
JP2023171324A Pending JP2023166014A (ja) | 2015-12-23 | 2023-10-02 | コラーゲン7組成物及びそれを用いる方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018533834A Active JP6943858B2 (ja) | 2015-12-23 | 2016-12-21 | コラーゲン7組成物及びそれを用いる方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023171324A Pending JP2023166014A (ja) | 2015-12-23 | 2023-10-02 | コラーゲン7組成物及びそれを用いる方法 |
Country Status (8)
Country | Link |
---|---|
US (3) | US10695395B2 (ja) |
EP (1) | EP3394095B1 (ja) |
JP (3) | JP6943858B2 (ja) |
CN (2) | CN108463470B (ja) |
CA (1) | CA3006998A1 (ja) |
IL (2) | IL259583B (ja) |
MX (1) | MX2018007468A (ja) |
WO (1) | WO2017112757A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3394095B1 (en) * | 2015-12-23 | 2023-09-27 | Phoenix Tissue Repair Inc. | Collagen 7 compositions and methods of using the same |
EP3946596A4 (en) * | 2019-03-27 | 2022-12-21 | Phoenix Tissue Repair, Inc. | SYSTEMS AND METHODS OF PRODUCING COLLAGEN COMPOSITIONS 7 |
AU2022366945A1 (en) | 2021-10-12 | 2024-05-23 | Phoenix Tissue Repair, Inc. | Collagen 7 protein replacement therapy |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005527503A (ja) * | 2002-02-27 | 2005-09-15 | イミユネツクス・コーポレイシヨン | ポリペプチド製剤 |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2757874B1 (fr) * | 1996-12-17 | 2003-04-25 | Biocem | Collagenes recombinants et proteines derivees produits par les plantes, leurs procedes d'obtention et leurs utilisations |
GB0216001D0 (en) * | 2002-07-10 | 2002-08-21 | Nat Blood Authority | Process and composition |
US20080287349A1 (en) * | 2003-05-09 | 2008-11-20 | Jeffrey Peterson | Fibroblast growth factor 20 and methods of use thereof |
EP2298287B1 (en) * | 2003-12-19 | 2018-04-11 | Novo Nordisk Health Care AG | Stabilised compositions of factor VII polypeptides |
JP4832107B2 (ja) * | 2006-02-23 | 2011-12-07 | ソニーケミカル&インフォメーションデバイス株式会社 | 実装方法 |
CN101627117B (zh) * | 2006-08-01 | 2013-10-30 | 奇尼塔二有限责任公司 | 医药制造方法 |
WO2011017070A1 (en) * | 2009-07-28 | 2011-02-10 | Merck Sharp & Dohme Corp. | Methods for producing high concentration lyophilized pharmaceutical formulations |
US8475824B2 (en) * | 2010-01-26 | 2013-07-02 | Warsaw Orthopedic, Inc. | Resorbable matrix having elongated particles |
WO2011113024A1 (en) * | 2010-03-11 | 2011-09-15 | University Of Southern California | Compositions and methods for healing of skin wounds |
US20130237485A1 (en) * | 2010-05-06 | 2013-09-12 | University Of Southern California | Methods and Agents for Enhancing Wound Healing |
JP5996631B2 (ja) * | 2011-04-20 | 2016-09-21 | サンド・アクチエンゲゼルシヤフト | TNFR:Fc融合タンパク質の安定した医薬液剤 |
BR112014010542A2 (pt) * | 2011-11-02 | 2017-04-18 | Halscion Inc | métodos e composições para tratamento de ferimento |
US20180104186A1 (en) * | 2013-03-13 | 2018-04-19 | University Of Miami | Methods and compositions for the treatment of epidermolysis bullosa |
CN104740612A (zh) * | 2013-12-31 | 2015-07-01 | 上海中信国健药业股份有限公司 | 一种受体抗体融合蛋白的液体制剂 |
WO2015157469A2 (en) * | 2014-04-08 | 2015-10-15 | University Of Southern California | Polypeptide compositions with type vii collagen fibronectin type iii- like repeats and treatment methods for wound closure and healing |
EP3394095B1 (en) * | 2015-12-23 | 2023-09-27 | Phoenix Tissue Repair Inc. | Collagen 7 compositions and methods of using the same |
JP6985282B2 (ja) * | 2016-03-16 | 2021-12-22 | フェニックス ティシュー リペア インコーポレイテッドPhoenix Tissue Repair, Inc. | 7型コラーゲンの精製方法 |
-
2016
- 2016-12-21 EP EP16880019.1A patent/EP3394095B1/en active Active
- 2016-12-21 CA CA3006998A patent/CA3006998A1/en active Pending
- 2016-12-21 US US16/065,512 patent/US10695395B2/en active Active
- 2016-12-21 MX MX2018007468A patent/MX2018007468A/es unknown
- 2016-12-21 CN CN201680075057.5A patent/CN108463470B/zh active Active
- 2016-12-21 JP JP2018533834A patent/JP6943858B2/ja active Active
- 2016-12-21 CN CN202111171969.1A patent/CN114225013A/zh active Pending
- 2016-12-21 WO PCT/US2016/067995 patent/WO2017112757A1/en active Application Filing
-
2018
- 2018-05-24 IL IL259583A patent/IL259583B/en unknown
-
2020
- 2020-05-15 US US16/875,223 patent/US20200316158A1/en not_active Abandoned
-
2021
- 2021-09-09 JP JP2021146575A patent/JP2021185201A/ja active Pending
-
2022
- 2022-01-27 IL IL290166A patent/IL290166A/en unknown
-
2023
- 2023-02-15 US US18/169,368 patent/US20230414698A1/en active Pending
- 2023-10-02 JP JP2023171324A patent/JP2023166014A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005527503A (ja) * | 2002-02-27 | 2005-09-15 | イミユネツクス・コーポレイシヨン | ポリペプチド製剤 |
Non-Patent Citations (1)
Title |
---|
MOLECULAR THERAPY, vol. 17,1, JPN6020033052, 18 November 2008 (2008-11-18), pages 26 - 33, ISSN: 0005071086 * |
Also Published As
Publication number | Publication date |
---|---|
US20230414698A1 (en) | 2023-12-28 |
CN108463470A (zh) | 2018-08-28 |
US20200316158A1 (en) | 2020-10-08 |
IL290166A (en) | 2022-03-01 |
JP6943858B2 (ja) | 2021-10-06 |
EP3394095A4 (en) | 2019-08-14 |
WO2017112757A1 (en) | 2017-06-29 |
MX2018007468A (es) | 2018-11-14 |
EP3394095B1 (en) | 2023-09-27 |
IL259583A (en) | 2018-07-31 |
IL259583B (en) | 2022-03-01 |
JP2019504043A (ja) | 2019-02-14 |
JP2023166014A (ja) | 2023-11-17 |
CN114225013A (zh) | 2022-03-25 |
CA3006998A1 (en) | 2017-06-29 |
US20190000912A1 (en) | 2019-01-03 |
US10695395B2 (en) | 2020-06-30 |
EP3394095A1 (en) | 2018-10-31 |
CN108463470B (zh) | 2021-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11633462B2 (en) | Pharmaceutical composition comprising plasminogen and uses thereof | |
JP2021185201A (ja) | コラーゲン7組成物及びそれを用いる方法 | |
JP6117811B2 (ja) | 糖尿病を処置するための製剤 | |
KR102579789B1 (ko) | C1 에스터라제 억제제 결핍과 관련된 장애의 예방 및 치료를 위한 c1-inh 조성물 및 방법 | |
JP6525987B2 (ja) | インスリングルリジンの安定製剤 | |
US20150150982A1 (en) | Pharmaceutical formulation for a therapeutic antibody | |
AU2021250949A1 (en) | Liquid Pharmaceutical Composition | |
JP6869255B2 (ja) | 凍結医薬製剤およびその使用 | |
JP2023123738A (ja) | 組換えvwfの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療 | |
JP6516855B2 (ja) | C1エステラーゼ阻害剤の医薬製剤 | |
EP3685850A1 (en) | Teriparatide-containing liquid pharmaceutical composition having excellent pharmacodynamics and/or stability | |
TW202134266A (zh) | 藉由投予重組vwf治療患有嚴重馮威里氏病之患者之經血過多 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211008 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211008 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221004 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221220 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230530 |